Showing 1 - 4 results of 4 for search 'M. Ritgen', query time: 0.05s
Refine Results
-
1
P681: EUROFLOW STANDARDIZATION TECHNIQUE AND NORMALIZATION PROCEDURES IN LONGITUDINAL FLOW CYTOMETRIC EXPRESSION ANALYSIS OF CD20 IN CLL PATIENTS RECEIVING ANTI-CD20 DIRECTED THERA... by P. J. Walter, A. Schilhabel, P. Cramer, J. von Tresckow, S. Kohlscheen, K. Fischer, B. Eichhorst, S. Böttcher, M. Brüggemann, M. Kneba, M. Hallek, M. Ritgen
Published 2022-06-01
Article -
2
S148: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 5-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY by O. Al-Sawaf, C. Zhang, S. Robrecht, A. Kotak, N. Chang, A.-M. Fink, E. Tausch, C. Schneider, M. Ritgen, K.-A. Kreuzer, B. Chyla, B. Eichhorst, Y. Jiang, S. Stilgenbauer, M. Hallek, K. Fischer
Published 2022-06-01
Article -
3
P652: MEASURING MINIMAL RESIDUAL DISEASE BEYOND 10-4 THROUGH IGHV LEADER-BASED NEXT GENERATION SEQUENCING IMPROVES PROGNOSTIC STRATIFICATION IN CHRONIC LYMPHOCYTIC LEUKEMIA by P. Hengeveld, M. van der Klift, P. M. Kolijn, F. Davi, F. Kavelaars, E. de Jonge, S. Robrecht, J. Assmann, L. van der Straten, M. Ritgen, P. Westerweel, K. Fischer, V. Goede, M. Hallek, M.-D. Levin, A. Langerak
Published 2022-06-01
Article -
4
S143: TRANSCRIPTOMIC CHARACTERIZATION OF MRD RESPONSE AND NON-RESPONSE IN PATIENTS TREATED WITH FIXED-DURATION VENETOCLAX-OBINUTUZUMAB by O. Al-Sawaf, H. Y. Jin, C. Zhang, Y. Choi, S. Balasubramanian, S. Robrecht, A. Kotak, N. Chang, A.-M. Fink, E. Tausch, C. Schneider, M. Ritgen, K.-A. Kreuzer, B. Chyla, J. Paulson, B. Eichhorst, S. Stilgenbauer, Y. Jiang, M. Hallek, K. Fischer
Published 2022-06-01
Article